Drug Discovery World
DECEMBER 16, 2022
The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases. . The post Biotech company raises $30M to target RNA modifying enzymes appeared first on Drug Discovery World (DDW).
The Pharma Data
JANUARY 5, 2021
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. The first identifies the 3D RNA motifs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JUNE 14, 2023
percent received approval from the US Food and Drug Administration (FDA) to treat dry eye disease. Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. Attendees will understand best practices for novel drug delivery design and development.
Delveinsight
JANUARY 7, 2021
Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs. Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The newer side of the pipeline points targeted oncology drugs. Terns raises USD 87 Million for NASH drugs. IND-enabling studies are underway.
Drug Discovery World
AUGUST 3, 2022
Emerging as a new treatment option in rare and orphan disease areas, oligonucleotide therapeutics have matured into a drug class with a broad indication spectrum. Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake.
The Pharma Data
MARCH 8, 2021
Of 202 treated participants, no safety signals have been identified and of the 4 serious adverse events reported, none were considered to be study drug related. This program included assays such as Big Blue and PIG-a designed to provide a robust measure of a drug or chemical’s ability to induce mutations in vivo. About Molnupiravir.
The Pharma Data
JULY 12, 2021
Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. For further information regarding our clinical trials, please visit [link] or [link]. About Molnupiravir.
Expert insights. Personalized for you.
52 
Let's personalize your content